logo
The Good Life: A Tough, but Promising Path Ahead for College Grads

The Good Life: A Tough, but Promising Path Ahead for College Grads

Newsweek22-05-2025

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Welcome to The Good Life! This week, we're talking about everything from the future facing college grads, the first FDA-cleared blood test for Alzheimer's, the price of a first date, digital detox tips, and more. We're glad you're here!
Tap here to get this newsletter delivered to your inbox.
Mike Segar/Reuters
The end of spring marks the start of a major new chapter for college seniors, as they prepare to leave campus and step into the 'real world." But instead of excitement, many are feeling growing anxiety about a job market that feels both unstable and confusing.
Hailey Washington, a senior majoring in marketing at Drexel University in Philadelphia, isn't bullish about her job prospects despite stellar undergraduate performance and indispensable industry experience from an internship at a luxury fashion brand.
"Most of my friends and myself do not have jobs lined up after graduation and are not getting interviews. We're all currently seeking part-time positions to build our resumes and to make some money as we search for full-time positions," Washington, 21, told Newsweek.
The jobless rate for workers aged 16 to 24 currently hovers below 10 percent, well above the national average of 4.2 percent, as the ascent of automation, global competition and overall economic upheaval have created a potent mix of trepidation and hope within the Class of 2025, often prompting a simple yet existential question: What happens now?
Read more from Newsweek's Joshua Rhett Miller.
Newsweek
This week, we learned that former President Joe Biden has been diagnosed with an aggressive form of prostate cancer that has metastasized to the bone. The announcement has sparked renewed attention to this serious disease, including one of the most common concerns: what are the warning signs?
It's a question that prostate cancer expert Dr. Ashutosh Tewari hears often from patients—but says it's a tough one to answer.
"That's the irony," Tewari told Newsweek. "It's a silent killer."
He explained that evidence of prostate cancer often won't appear until it is too late and the cancer has already grown, possibly to the point of being incurable.
"So the message here is don't expect cancer to declare itself—you should go out and look for it, you should understand the risk," he said.
Read more from Newsweek's Lauren Giella.
Digital Detox: How to Save Yourself from Too Much Screen Time
Do you have an unhealthy relationship with your phone?
It's okay if you think so, we're not judging—because you're not alone. In 2025, the average American adult spends 7 hours and 4 minutes a day looking at screens—basically an entire workday or a night's sleep. Of that time, 5 hours and 16 minutes are spent on phones, a 14% increase from the year prior, with health concerns ranging from high blood pressure to obesity to eye strain: the culprit being sitting down indulging in too much screen time.
And it's not just adults. Screen time is skyrocketing among younger generations too, and this could lead to trouble if we're not careful. Studies have linked excessive screen use in preteens to a higher risk of developing manic symptoms.
So how do we fix this? After all, screens are everywhere, right?
Avoiding technology completely may not be realistic—but taking baby steps can benefit your overall health. Here are some tips:
Set Tech-Free Zones
Designate spaces in your home where technology is completely off-limits—no phones, no tablets, not even a smartwatch. Great options include the dinner table, a reading nook or bedroom. Enforce these boundaries with tools like iOS Screen Time or Android's Digital Wellbeing—no willpower is required there.
Schedule Screen-Free Time
This one's easy. Choose a consistent window each day to unplug completely. Whether it's 30 minutes in the morning or an hour before bed, use this time to read, reflect or simply unwind without screens.
Be Mindful With Your Tech
Stop! Before reaching for your phone, pause. Ask yourself: Why am I doing this? If it's out of boredom or habit, consider another activity. Practicing mindfulness around your tech use can significantly improve your mental well-being.
Cut Back on Social Media
If you're a heavy social media user, consider limiting yourself to 30 minutes a day. Research shows that people who reduce social media use report less loneliness and depression—and a whole lot less FOMO.
Go Outside
This one's simple: spend time in nature. Even just 20 minutes a day—about two hours per week—can boost both your mental and physical health. Watch the clouds, feel the grass, take a walk. It all helps.
Declutter Digitally
And this is just a final tip when you are using screens. That inbox with 2,000 unread emails? It's probably stressing you out more than you realize. Take time to clear out your digital clutter—emails, unused apps, old files—and you'll likely feel a lot lighter, instantly.
In other news...
First blood test for Alzheimer's: The FDA has cleared marketing for the first-ever blood test to help diagnose Alzheimer's in people showing symptoms. The new test is set to create more accessible diagnostic results and decrease the reliance on more invasive testing. Read more.
The FDA has cleared marketing for the first-ever blood test to help diagnose Alzheimer's in people showing symptoms. The new test is set to create more accessible diagnostic results and decrease the reliance on more invasive testing. Read more. Love does cost a thing: What's your ideal first date—coffee, cocktails, a fancy dinner? Turns out, Americans are willing to spend big to impress a match—$125 on average! But how much really depends on where you live. Here's the breakdown.
This is a preview of The Good Life—Tap here to get this newsletter delivered straight to your inbox.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Indivior to delist from London Stock Exchange, maintain Nasdaq listing
Indivior to delist from London Stock Exchange, maintain Nasdaq listing

Yahoo

time25 minutes ago

  • Yahoo

Indivior to delist from London Stock Exchange, maintain Nasdaq listing

(Reuters) -Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align with its U.S.-centric business. The company, known for its opioid addiction treatment, joins a growing number of companies delisting from London, as lower valuations and weak investor appetite continue to drive firms toward U.S. markets. Shares of Indivior, which floated in London in late 2014, have dropped more than 60% from record highs hit in June 2018. The company said over 80% of its revenue now comes from the U.S., with the Nasdaq accounting for about 75% of recent trading volumes. The delisting aims to streamline operations and reflect the company's strategic focus on the U.S. market, it said. Indivior moved its primary listing to the United States last year. The decision to delist from London comes just months after Indivior overhauled its management. Earlier this year, it appointed David Wheadon as chair and Joe Ciaffoni as CEO. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Hims & Hers to cut 68 employees, or 4% of workforce, Reuters reports
Hims & Hers to cut 68 employees, or 4% of workforce, Reuters reports

Business Insider

time27 minutes ago

  • Business Insider

Hims & Hers to cut 68 employees, or 4% of workforce, Reuters reports

Hims & Hers will cut 68 employees, or about 4% of its workforce, as it adjusts to the U.S. ban on manufacturing mass copies of Wegovy, Amina Niasse of Reuters reports. These changes are focused on sharpening how we execute, without affecting our priorities or the specialties we're committed to,' a company spokesperson said regarding the layoffs, according to Reuters. Confident Investing Starts Here:

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

Business Upturn

time38 minutes ago

  • Business Upturn

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

By GlobeNewswire Published on June 2, 2025, 10:15 IST Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile. 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients,' said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. 'These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients.' This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer. Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year. About PSMAddition study PSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3. About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan) Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414). Novartis and radioligand therapy (RLT) Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/ Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249 # # # Novartis Media Relations E-mail: [email protected] Novartis Investor RelationsCentral investor relations line: +41 61 324 7944 E-mail: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store